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Introduction: Given the physiological role of placental growth hormone (PGH) during intrauterine
development and growth, genetic variation in the coding Growth hormone 2 (GH2) gene may modulate
developmental programming of adult stature. Two major GH2 variants were described worldwide,
determined by single polymorphism (rs2006123; c.171 þ 50C > A). We sought to study whether GH2
variants may contribute to adult anthropometric measurements.
Methods: Genotyping of GH2 SNP rs2006123 by RFLP, testing its genetic association with adult height
and Body Mass Index (BMI) by linear regression analysis, and combining the results of three individual
study samples in meta-analysis.
Study samples: HYPEST (Estonia), n ¼ 1464 (506 men/958 women), CADCZ (Czech), n ¼ 871 (518/353);
UFA (Bashkortostan), n ¼ 954 (655/299); meta-analysis, n ¼ 3289 (1679/1610).
Results: Meta-analysis across HYPEST, CADCZ and UFA samples (n ¼ 3289) resulted in signiﬁcant asso-
ciation of GH2 rs2006123 with height (recessive model: AA-homozygote effect: beta (SE) ¼ 1.26 (0.46),
P ¼ 5.90  103; additive model: A-allele effect: beta (SE) ¼ 0.45 (0.18), P ¼ 1.40  102). Among men
(n ¼ 1679), the association of the A-allele with taller stature remained signiﬁcant after multiple-testing
correction (additive effect: beta ¼ 0.86 (0.28), P ¼ 1.83  103). No association was detected with BMI.
Notably, rs2006123 was in strong LD (r2  0.87) with SNPs signiﬁcantly associated with height
(rs2665838, rs7209435, rs11658329) and mapped near GH2 in three independent meta-analyses of GWA
studies.
Conclusions: This is the ﬁrst study demonstrating a link between a placental gene variant and pro-
gramming of growth potential in adulthood. The detected association between PGH encoding GH2 and
adult height promotes further research on the role of placental genes in prenatal programming of human
metabolism.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The human Growth hormone/Chorionic somatomammotropin
(hGH/CSH) genes belong to a rapidly evolving primate-speciﬁc gene
cluster spanning 48 kb at 17q22-24. In most mammals, a single GH1372 7420286.
(M. Laan).
r Ltd. Open access under CC BY-NC-Ngene encodes the pituitary growth hormone (GH), whereas in pri-
mates, novel placenta-speciﬁc GH-related genes have arisen
through gene duplications [1]. In humans,GH/CSH cluster consists of
ﬁve highly homologous (91e97%) and structurally similar genes:
GH1, GH2, CSH1, CSH2 and CSHL1 (chorionic somatomammotropin-
like 1) [2]. It is well known that pituitary GH (also known as so-
matotropin) promotes postnatal growth of skeletal and soft tissue,
and acts as an important regulator of immune function, bone
turnover andmusclemass. GHdeﬁciency (1:4000e1:10,000/births)
is associated with short stature [3] and common GH1 substitutions
have been shown to contribute to height determination [4].
In the humanplacenta, the expression of fourGH/CSH genes (GH2,
CSH1, CSH2, CSHL1) is coordinately induced during fetal developmentD license.
Table 1
Anthropometric characteristics of the study samples.
Parametera HYPEST CADCZ UFA
All Men Women All Men Women All Men Women
No of subjects 1464 506 958 871 518 353 954 655 299
Age (y) 47.5  13.4 45.3  13.6 48.7  13.2 50.0  10.6 51.2  9.8 48.1  11.4 54.1  17.1 50.3  15.9 62.3  17.0
Height (cm) 169.6  9.3 178.9  6.9 164.6  6.1 172.4  8.7 177.3  6.9 165.3  5.8 167.6  8.2 169.1  7.5 164.4  8.6
BMI (kg/m2) 26.3  4.8 27.0  3.9 26.0  5.2 27.0  4.4 27.7  3.8 26.1  5.0 27.9  3.9 27.6  3.7 28.7  4.4
a For each parameter mean  SD is shown; y, age in years; BMI, body mass index (kg/m2).
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their expression proﬁle exhibits pleiotropic effects at the maternale
fetal interface in regulating of fetal growth andmodulatingmaternal
metabolism [6e9]. Two of these, CSH1 and CSH2, encode jointly an
identical protein chorionic somatomammotropin (CSH, also known
as placental lactogen, PL). CSHL1 was originally considered as a
pseudogene, although low levels of its expression in placenta have
been reported [8]. GH2 encodes placental GH (PGH), which pro-
gressively replaces maternal pituitary GH from mid-gestation on-
wards, peaking towards term [10,11]. Only 13 amino acid residues
constitute the difference between PGH and GH. To execute its func-
tion, PGH binds to GH cell surface receptors (GHR) with similar af-
ﬁnity to pituitary GH [6]. Interestingly, secreted PGH is found
predominantly, but not exclusively, in maternal circulation [12,13].
Maternal PGH serum levels have been positively correlated with in-
fant birth weight [11,12,14]. Signiﬁcantly lower placental expression
of GH2 and reduced levels of circulating PGH have been reported in
women with fetal intrauterine growth retardation/small-for-gesta-
tional-age pregnancies [8,12,14].
We hypothesized that given the physiological role of PGH during
intrauterine development, the genetic variation in the GH2 gene
may modulate growth in utero and in early infancy, therefore
possibly affecting the developmental programming of human stat-
ure in adulthood. However, in contrast to the pituitary-expressed
GH1, there are limited data on the impact of polymorphisms in the
placental hGH/CSH genes on intrauterine growth and programming
of the postnatal metabolism [15]. Detailed research on hGH/CSH
cluster has been hindered by its complex genomic structure rich in
repetitive genic and intergenic sequence fragments. Our pioneer
study had revealed that the duplicated hGH/CSH genes exhibit
substantial heterogeneity in diversity patterns and low linkage
disequilibrium (LD) between allelic variants, driven by the interplay
between active intergenic gene conversion and locus-speciﬁc se-
lective pressures [16]. For the GH2 gene, only two major gene vari-
ants were described, determined by the allelic status of one
polymorphism (rs2006123; c.171þ50C> A) located 50 bp from the
donor splice site within intron 2 (original nomenclature [16],
g.943C>A).GH2 rs2006123 alleleswere differentially distributed in
studied populations: 92% of the Chinese Han individuals carried the
ancestral C-allele, whereas the derived A-allele was enriched in
AfricanMandenkalu (carrier frequency 95%). In European Estonians
both alleles were commonly represented (C, 66%; A, 34%). As other
hGH/CSH genes showed no or low intercontinental differentiation, it
was suggested that the observedGH2 variationpatternmight reﬂect
regional population-speciﬁc selection.
The present study aimed to test the association between human
PGH coding GH2 intron 2 polymorphism rs2006123 and anthro-
pomorphic phenotypes (height, BMI) in three Eastern/Central Eu-
ropean sample sets and in the subsequent meta-analysis (total
sample size, n ¼ 3289). We report signiﬁcant association between
GH2 rs2006123 and adult height, and show that the studied GH2
variant is in strong LD (r2 > 0.8) with top hits from three inde-
pendent meta-analysis of genome-wide association studies
(GWAS) for height, mapped within the hGH/CSH gene cluster(rs2665838 [17]) or to its vicinity (<250 kb: rs7209435 [18];
rs11658329 [19]).
2. Materials and methods
2.1. Study groups
The analyzed sample collections HYPEST (Estonians), CADCZ (Czech) and UFA
(Bashkirs and Tatars from Volga-Ural region, Russia) represent populations of
Eastern/Central European origin and their basic characteristics are provided in
Table 1. The recruitment of the three sample sets has been carried out in compliance
with the Helsinki Declaration and participants have given the written informed
consent. The HYPEST study has been approved by the Ethics Committee on Human
Research of University of Tartu (permissions 122/13, 22.12.2003; 137/20,
25.04.2005). The CADCZ study has been approved by the Ethics Committee of
Charles Universityd1st Faculty of Medicine (December 1996) and the UFA study by
the Independent Ethics Committee of the Institute of Biochemistry and Genetics, Ufa
Scientiﬁc Centre of Russian Academy of Sciences, Ufa, Russia (permission no. 5,
25.01.2005).
Originally, HYPEST subjects were recruited across Estonia, North-Eastern Europe
during 2004e2007 (1966 individuals, age range 18e85 years) with the main aim to
analyze genetic-epidemiological risk factors for cardiovascular disease in Estonian
population [20]. In the current study, the total number of genotyped HYPEST sub-
jects was n ¼ 1464 (aged 47.5  13.4 years) including 506 men (aged 45.3  13.6
years) and 958 women (aged 48.7  13.2 years). The CADCZ samples have been
recruited across Czech Republic, Central Europe by the Cardiology Department of the
2nd Clinic of Internal Medicine, Faculty Hospital Královské Vinohrady in Praguewith
the main aim to study genetic factors relating to homocysteine metabolism in cor-
onary artery disease and details are published elsewhere [21]. The number of CADCZ
samples available for genotyping in the current study was 871 (aged 50.0  10.6
years), including 518 men (aged 51.2  9.8 years) and 353 women (aged 48.1 11.4
years). UFA sample is comprised of subjects recruited in Bashkortostan, the Volga-
Uralic region of Russia, located at the border of Eastern Europe and Asia (prof. E.
Khusnutdinova and collaborators). In this study, 954 of Bashkortostan samples
(n¼ 464 Tatars, n¼ 490 Bashkirs) were genotyped (aged 54.117.1 years). Analyzed
UFA samples included 655 men (aged 50.3  15.9 years) and 299 women (aged
62.3  17.0 years).
At the recruitment, anthropometric data (height in cm, weight in kg) of each
participant of the three studies were documented. In order to consider in association
testing both genders together, in addition to the direct height measurements, the
transformed values were used as recommended [17]. Z-score (standard deviation
score) for height was calculated as the subject’s height minus themean height in the
sex appropriate subsample of each study divided by the standard deviation of that
mean. Body mass index (BMI) was calculated as weight (kg) divided by height
squared (m2).
2.2. Genotyping
In order to exclude ampliﬁcation of other highly homologous hGH/CSH genes,
the genotyping protocol of GH2 rs2006123 SNP included long-range PCR to amplify
speciﬁcally the entire GH2 gene region (5634 bp product [16]; forward primer: 50-
AGGTCTGGAAAGGAGGAGACAAAAGAG-30 , reverse primer: 50-TTGAATTA-
GACTTGGGATTCTCCTGACA-30), and allele-speciﬁc restriction fragment length
polymorphism (RFLP) analysis (Supplemental Figs. S1eS2). In case the long-range
PCR had resulted in insufﬁcient product quantity for the RFLP detection, nested
PCR (1855 bp product; forward primer: 50-GCTTGTGGTCCGTGTCTGTTCC-30 , reverse
primer: 50-GGTGGCGATAGACGTTGCTGTCC-30) was applied to further amplify the
DNA fragment involving the targeted SNP. PCR conditions are described in
Supplemental Text S1.
The ampliﬁed product was digested with FastDigest XapI restriction endonu-
clease according to manufacturer’s recommendations (Thermo Fisher Scientiﬁc,
Lithuania). Allele-speciﬁc RFLP products were separated by electrophoresis on a 1e
2% agarose gel and 0.5xTris/Borate/EDTA buffer. The following fragments were
detected in the RFLP analysis of (i) long-range PCR: 2658, 1626, 541, 484, 218, 107 bp
(C-allele); 1626, 1614, 1044, 541, 484, 218, 107 bp (A-allele) (Supplemental Fig. S1A)
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(Supplemental Fig. S1B). In developmental phase of the RFLP-based genotyping
assay, a subset of samples were sequenced for the quality control and to verify few
ambiguous genotypes using previously published sequencing primers and condi-
tions [16].
2.3. Data analysis
Estimation of allele frequencies, conformance to HardyeWeinberg Equilibrium
(HWE; c2, P > 0.05) and association testing of the GH2 rs2006123 with anthropo-
metric characteristics using linear regression under additive and recessive genetic
models was implemented in PLINK v1.07 software http://pngu.mgh.harvard.edu/
purcell/plink/ [22]. Additive genetic model assumes that having two copies of the
minor allele has twice the effect of having a single copy of a minor allele, while
recessive model assumes that only having two copies of a minor allele has an effect
on phenotype. In association testing in the full sample, adjustment for age and
gender were applied; analyses among men or women, and in the full sample using
transformed values (Z-score for height) were adjusted only for age. Bonferroni
threshold for multiple testing was estimated for the discovery analysis a ¼ 0.05/[2
(models)  2 (parameters: height, BMI)  2 (gender)] ¼ 6.25  103, and for the
meta-analysis a ¼ 0.05/[3 (studies)  2 (models)  2 (parameters: height, BMI)  2
(gender)] ¼ 2.08  103. Results were combined in a meta-analysis using the
inverse-variance method under ﬁxed-effects model using R, ver. 2.13.1 (R Devel-
opment Core Team 2011, http://www.r-project.org/). Presence of heterogeneity in
the meta-analysis was assessed by Cochran’s Q and I2 statistics [23]. Power calcu-
lations for meta-analysis were performed in R (pwr package). Height distribution
data was used to estimate f2 values assuming additive genotype effects.
Linkage disequilibrium (LD; r2) in the hGH/CSH region was calculated using
1000GENOMES:pilot_1_CEU_low_coverage_panel dataset generated by sequencing
the HapMap CEPH (Centre d’Etude du Polymorphisme Humain) samples repre-
senting Northern and Western European ancestry (n ¼ 60; http://browser.
1000genomes.org/index.html). The LD calculations using the above-mentioned
data included also top SNPs associated with height within or in the vicinity of
hGH/CSH region in the published meta-analysis of GWAS studies (rs2665838 [17];
rs7209435 [18]; rs11658329 [19]; rs2854160 [24]). Additionally, LD between GH2
rs2006123 and SNPs within the GH1 and GH2 genes was estimated using published
resequencing dataset from Ref. [16]. All LD plots were composed using the Haplo-
view 4.2 program (www.broadinstitute/haploview/haploview) [25].
Sequence alignments were performed using theWeb-based ClustalW2 program
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Statistical difference between men
and women in the distribution of rs2006123 genotype frequencies was assessed
using c2-test implicated in Genepop 4.2 software (http://kimura.univ-montp2.fr/
wrousset/Genepop.htm; “population differentiation” option). The testing condi-
tions: dememorization ¼ 10,000, batches ¼ 1000, iterations ¼ 10,000.
3. Results
3.1. GH2 rs2006123 genotype and allele frequencies
The HYPEST (n ¼ 1464), CADCZ (n ¼ 871), and UFA (n ¼ 954)
samples were genotyped for the GH2 rs2006123 polymorphism
(intron 2; c.171 þ 50C > A; original nomenclature g.943C > A [16])
using the combination of gene-speciﬁc long-range and nested PCR
followed by allele-speciﬁc RFLP. In all sample sets, the distribution
of rs2006123 genotypes was in accordance with HWE (P > 0.05;
Table 2). Minor A-allele frequency of the GH2 rs2006123 poly-
morphism exhibited a gradient from Volga-Ural to Central Europe
(UFA 20.4%, HYPEST 25.4%, CADCZ 30.4%; Table 2). Genotype fre-
quency distributions among male and female subjects in all threeTable 2
Allele and genotype frequencies of the GH2 rs2006123.
Population N Allele freq
C
HYPEST Estonia 1464 % 74.6
(N) (2185)
CADCZ Czech 871 % 69.6
(N) (1213)
UFA Bashkortostan 954 % 79.6
(N) (1518)
N, number of genotyped subjects in each sample set.
a Data presented as percentage with number of allele/genotype carriers in brackets.
b HWE, P-value of the c2-test for Hardy-Weinberg-Equilibrium.sample sets were statistically similar (c2-test, P > 0.27;
Supplemental Table S1).
3.2. GH2 rs2006123 is associated with adult height
In the discovery analysis of HYPEST samples (Estonians), GH2
rs2006123 SNPwas signiﬁcantly associatedwithmale height under
additive genetic model (n ¼ 506; A-allele effect: beta (SE) ¼ 1.52
(0.5); P ¼ 2.54  103), whereas no association was detected in the
female-only analysis (n ¼ 958; Table 3). Although in the replication
samples (UFA, Bashkortostan: n ¼ 655 men, n ¼ 299 women;
CADCZ, Czech: n ¼ 518 men, n ¼ 353 women; Table 1) the associ-
ation testing did not reach statistical signiﬁcance, ﬁve of the six
analyzed groups under the additive model and all groups under the
recessive model showed consistent trend (positive beta) of asso-
ciation with height (Table 3).
Prior to meta-analysis, the consistency of effects across study
groups was estimated. For all performed meta-analysis tests, the
calculated heterogeneity statistic was indicative to the consistency
of studies’ results (I2¼ 0%). In the meta-analysis across the HYPEST,
CADCZ and UFA men (n ¼ 1679), the association of the GH2
rs2006123 A-allele with taller stature was enhanced (additive ef-
fect: beta ¼ 0.86 (0.28), P ¼ 1.83  103) and remained statistically
signiﬁcant after multiple testing correction (Table 3). In meta-
analysis across women (n ¼ 1610), the association was not statis-
tically signiﬁcant.
Based on direct height measurements, the HYPESTmen carrying
AA-genotype were in average 2.7 cm taller than the CC-
homozygote men, and the mean height difference between AA-
and CC-homozygote womenwas 1.6 cm. In the UFA sample, the AA-
compared to CC-homozygotes were in average 2.4 cm and 1.5 cm
taller among men and women, respectively; and in the CADCZ
sample the estimated height difference was 1.8 cm (male) and
0.7 cm (female) (Table 4). Alternative testing of the full study
sample based on the calculated Z-scores instead of raw height
measurements (in cm) further supported the detected association
between GH2 rs2006123 and adult height (Table 5).
3.3. No association of GH2 rs2006123 with BMI
The GH2 rs2006123 was not associated with BMI in any of the
analyzed studies (HYPEST, UFA, CADCZ) either in the full sample or
in sex-speciﬁc sub-samples (Supplemental Tables S2eS3).
3.4. GH2 rs2006123 is in strong LD with top hits from meta-
analysis of GWA studies for height within or nearly the hGH/CSH
region
Intergenic SNPs within the hGH/CSH cluster or in the vicinity
have been associated with adult height in several independent
meta-analysis of conducted genome-wide association studiesuenciesa Genotype frequenciesa HWEb
A C/C C/A A/A P-value
25.4 54.9 39.4 5.7 0.129
(743) (804) (577) (83)
30.4 47.9 43.5 8.6 0.471
(529) (417) (379) (75)
20.4 64.3 30.6 5.1 0.073
(390) (613) (292) (49)
Table 3
Association testing of the GH2 rs2006123 with measured adult height (in cm).
Study N Additive model Recessive model
Beta (SE) 95% CI P-value Beta (SE) 95% CI P-value
HYPEST All 1464 0.43 (0.26) [0.07, 0.94] 9.09  102 1.41 (0.67) [0.10, 2.73] 3.52 3 10L2
Men 506 1.52 (0.50) [0.54, 2.50] 2.54 3 10L3* 2.07 (1.51) [0.89, 5.04] 1.72  101
Women 958 0.05 (0.29) [0.63, 0.52] 8.53  101 1.21 (0.73) [0.22, 2.63] 9.67  102
CADCZ All 871 0.27 (0.33) [0.37, 0.91] 4.06  101 0.74 (0.74) [0.72, 2.20] 3.20  101
Men 518 0.37 (0.45) [0.51, 1.25] 4.16  101 0.64 (1.03) [1.38, 2.66] 5.34  101
Women 353 0.08 (0.46) [0.82, 0.99] 8.58  101 0.75 (1.05) [1.31, 2.80] 4.78  101
UFA All 954 0.81 (0.43) [0.04, 1.66] 6.25  102 2.05 (1.15) [0.21, 4.31] 7.62  102
Men 655 0.83 (0.50) [0.14, 1.80] 9.47  102 2.39 (1.32) [0.20, 4.97] 7.08  102
Women 299 0.66 (0.86) [1.03, 2.35] 4.46  101 1.27 (2.29) [3.21, 5.75] 5.79  101
Meta-analysis All 3289 0.45 (0.18) [0.09, 0.81] 1.40 3 10L2 1.26 (0.46) [0.36, 2.15] 5.90 3 10L3
Men 1679 0.86 (0.28) [0.32, 1.41] 1.83 3 10L3** 1.47 (0.71) [0.07, 2.87] 3.93 3 10L2
Women 1610 0.04 (0.24) [0.43, 0.50] 8.79  101 1.07 (0.58) [0.06, 2.20] 6.37  102
Linear regression (age and gender as covariates) was used to test association with height under additive and recessive genetic models. Effect is given as beta, SE. P < 0.05 is
highlighted in bold and P-values lower than Bonferroni threshold for multiple testing correction in the discovery analysis (a ¼ 6.25  103) and in the meta-analysis
(a ¼ 2.08  103) are indicated with asterisks (*) or (**), respectively. Meta-analysis of across individual studies (HYPEST, CADCZ, UFA) was performed using an inverse-
variance method under ﬁxed-effect model. N, number of subjects; SE, standard error, CI, conﬁdence interval.
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rs7209435 [18]; rs11658329 [19]; rs2854160 [24]). We estimated
the strength of LD between the GH2 rs2006123 and the sur-
rounding SNPs using the 1000Genomes dataset for the subjects of
European origin (CEPH; n ¼ 60). Consistent with the previous
report in Estonians, Mandenkalu and Chinese Han [16], also in the
1000Genomes dataset the entire hGH/CSH gene region was char-
acterized by weak LD (Supplemental Fig. S3). Notably, the GH2
rs2006123 showed strong LD with three previously identiﬁed SNPs
associated with adult height within or near the hGH/CSH cluster:
rs2665838 (r2¼ 0.87,w7.2 kb upstream from GH2), and rs7209435,
rs11658329 (r2 ¼ 0.92, within the MAP3K3 gene w245 kb and
w195 kb upstream from rs2006123, respectively) (Fig. 1). The GH2
rs2006123 was not in LD with the hGH/CSH cluster SNP rs2854160
detected in combined GWA results for height from 9 studies of
individuals of African descent (r2 ¼ 0.19, CSH1-CSHL1 intergenic
region).
Importantly, in the 1000Genomes dataset the SNPs within or
nearby the hGH/CSH region reported in four meta-analyses of
GWAS data to be associated with height, completely lacked (r2 ¼ 0)
or exhibited low LD (r2  0.3) with SNPs in GH1 encoding the pi-
tuitary growth hormone (Fig. 1, Supplemental Fig. S3). Also, in the
published resequencing study of the hGH/CSH genes [16], almost no
(r2  0.09 for 14 of 18 SNPs) or low LD was estimated between the
GH2 rs2006123 and SNPs in the GH1 gene (average r2¼ 0.066) or its
upstream region (r2 ¼ 0.19), and other SNPs the GH2 gene
(r2 ¼ 0.025) (Supplemental Table S4).
4. Discussion
The current study reports the signiﬁcant effect of the genetic
variant (rs2006123; c.171 þ 50C > A) in intron 2 of GH2 gene
encoding placental growth hormone (PGH) to modulate the adult
height. To our knowledge, this is the ﬁrst study to demonstrate a
link between a polymorphism in a gene with known expressionTable 4
Measured height in subgroups carrying the alternative GH2 rs2006123 genotypes.
Genotype HYPEST CADCZ
Men Women Men
N: CC, CA, AA 281, 206, 19 523, 371, 64 255, 21
CC 178.1  6.8a 164.7  5.8 176.9 
CA 179.8  7.0 164.2  6.3 177.4 
AA 180.8  5.0 166.3  6.3 178.7 
a Data is provided as mean  SD of height in centimeters (cm); N, number of subjectsrestricted to the placenta during prenatal period and the pro-
gramming of the growth potential in adulthood. Humans with the
derived GH2 rs2006123 A-allele appeared to be taller and the effect
was stronger among men. In meta-analysis across the three study
samples of Eastern/Central European origin (n¼ 3289), the effect of
the A-variant was detected 0.45 cm per allele (P ¼ 1.40  102) and
1.26 cm for the AA-genotype (P ¼ 5.90  103); whereas among
men (n ¼ 1679) the A-allele carrier effect was 0.86 cm per allele
(P ¼ 1.83  103) and 1.47 cm for AA-homozygotes
(P ¼ 3.93  102). The limitation of modest sample size possibly
affected proper association testing with female height
(Supplemental Fig. S4). Still, the observed effect sizes in women
showed consistent non-signiﬁcant trend (positive beta) of associ-
ation with height under the recessive model (meta-analysis: beta
(SE) ¼ 1.07 (0.58); P ¼ 6.37  102; Table 3). Unfortunately, further
postnatal inﬂuences were not known for the study groups and thus,
could not be ruled out as additional modiﬁers of the study outcome.
Overall, the present results contribute to a larger array of genetic
effects reported to be involved in human adult height determina-
tion [17e19,24].
The studied GH2 polymorphism rs2006123 (C/A; located in
intron 2, 50 bp from donor splice site) is determining the two main
GH2 variants in humans [16]. It shows high allelic differentiation
among world populations and possible balancing selection acting
on its genetic variation. Whereas in Asia the prevalence of the
derived A-allele is low (8% in Han Chinese and Japanese; dbSNP,
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?
rs¼2006123), it represents the major GH2 variant in Africa (Sene-
galese Mandenkalu 85%, Nigerian Yorubans 79%). In Europe, there
appears to be a West-East gradient of the A-allele frequency, from
30% in Central-Europe to 20% at the Volga-Ural region bordering
Europe and Asia. In human-chimpanzee comparison, GH2 is the
most conserved gene in the GH/CSH cluster and so far only chro-
mosomes with C-allele at the position c.171 þ 50C > A have been
described [26]. Also, all the rest of the highly homologous genes inUFA
Women Men Women
8, 45 162, 161, 30 413, 208, 34 200, 84, 15
7.4 165.3  5.7 168.8  7.7 164.2  8.8
6 .3 165.1  5.7 169.3  7.1 164.8  8.5
6.5 166.0  7.1 171.2  7.8 165.7  7.4
in each genotype group (CC, CA, AA).
Table 5
Association testing of the GH2 rs2006123 with adult height based on calculated Z-scores (Standard deviation scores).
Study N Additive model Recessive model
Beta (SE) 95% CI P-value Beta (SE) 95% CI P-value
HYPEST 1464 0.066 (0.040) [0.012, 0.145] 1.01  101 0.238 (0.105) [0.032, 0.444] 2.36 3 10L2
CADCZ 871 0.038 (0.050) [0.061, 0.136] 4.56  101 0.113 (0.115) [0.113, 0.338] 3.27  101
UFA 954 0.103 (0.055) [0.005, 0.210] 6.20  102 0.264 (0.146) [0.023, 0.550] 7.13  102
Meta-analysis 3289 0.067 (0.027) [0.013, 0.120] 1.44 3 10L2 0.199 (0.069) [0.065, 0.333] 3.64 3 10L3
Linear regression (age as covariate) was used to test association with height under additive and recessive genetic models. Effect is given as beta, SE. P < 0.05 is highlighted in
bold. Meta-analysis of across individual studies (HYPEST, CADCZ, UFA) was performed using an inverse-variance method under ﬁxed-effect model.
N, number of subjects; SE, standard error, CI, conﬁdence interval.
Y. Timasheva et al. / Placenta 34 (2013) 995e1001 999the hGH/CSH cluster (GH1, CSH1, CSH2, CSHL1) aremonomorphic for
the C-nucleotide at this position (Supplemental Fig. S5). In case the
C-allele is considered as ancestral, the derived A-allele associated
with a taller statue, arose as a novel mutation among humans.
PGH secreted by syncytiotrophoblast functions as an insulin
antagonist, controls maternal Insulin Growth Factor 1 (IGF-1) pro-
duction and glucose utilization in pregnancy [6,7]. The induction of
PGH by glucose deprivation provides a feedback loop to ensure a
delivery of nutrients to developing fetus. Multiple studies have
provided convincing evidence for a positive correlation between
maternal serum PGH concentration and birth-weight [11,12,14]. InFig. 1. Pairwise LD plot (296 kb region; 17q23.3) including SNPs in the GH1 and GH2 gen
mapped within or nearby the hGH/CSH genome cluster (rs2665838 [17], rs7209435 [18], rs11
and the GWAS top-SNPs are marked with an asterisk. SNPs in strong LD (r2 > 0.8) are boxed.
the gene location and transcriptional orientation. The location of SNPs rs2665838 and rs285
was calculated based on 1000GENOMES:pilot_1_CEU_low_coverage_panel dataset containin
individual squares of the LD triangle represent the estimated r2 (%) values between SNP p
squares, r2 ¼ 100%).addition, it has been shown that transgenic mice over-expressing
the gene encoding for PGH became larger than their normal lit-
termates and they are at risk to develop insulin resistance in later
life [27]. The observed effects of PGH speak for its inﬂuence on
growth process, thus explaining the association found with the
adult height, but the exact molecular mechanisms of the effect are
yet to be discovered. However, based on the accumulated evidence,
it has been concluded that altered metabolism of PGH in humans
may lead to consequences not only in fetal growth and gestational
metabolism, but also in programming the birth-weight of a
newborn and long-term metabolic function [7]. Unfortunately, thees and top-hits from four independent meta-analysis of GWA studies of adult height
658329 [19], rs2854160 [24]). The GH2 rs2006123 is indicated with an oval dashed line
The genomic context of the region is shown above the LD plot. Solid arrows indicate to
4160 within the zoomed-in hGH/CSH gene cluster is shown with dashed arrows. LD (r2)
g HapMap individuals with European ancestry (CEPH; n ¼ 60). Numbers shown on the
airs, scaling from no LD (white squares, r2 ¼ 0) to complete allelic association (black
Y. Timasheva et al. / Placenta 34 (2013) 995e10011000datasets of the current study did not allow addressing the associ-
ation of GH2 polymorphism rs2006123 with birth weight and
height.
The secretion of PGH is inhibited by glucose in vitro and in vivo
[28], indicating that maternal nutrition, food availability and diet
may affect PGH synthesis. Different GH2 expressional variants
could have had a selective advantage to guarantee the optimal birth
weight for a given population environment and life-style. However,
as human dietary habits and lifestyle have changed tremendously
in past centuries, the genetic composition evolved to support
normal growth axis even in nutrient-limited situations may
contribute to the programming of accelerated growth in a nutrient-
abundant environment. Notably, a recent study showed that fre-
quencies of SNP alleles associated with increased height were
systematically elevated in Northern compared with Southern Eu-
ropeans mirroring the intra-European height differences and being
consistent with weak selection on these genetic variants [29].
Several meta-analyses of GWA studies have mapped genetic
variants contributing to height determination within (intergenic
region) or in the vicinity (within 245 kb) of the hGH/CSH gene
cluster. The studied GH2 intronic variant rs2006123 was in strong
LD (r2  0.87) with three of the four reported top hits mapped to
this region to be associated with height (rs2665838 [17];
rs7209435 [18]; rs11658329 [19]). Thus, the current paper is
essentially providing important experimental support for an in
silico imputation, an essential step in meta-analyses of GWAS
datasets. This observation favors the scenario that the reported
GWAS associations with height may be attributable to the func-
tionality of the GH2 rs2006123 alternative alleles, although it does
not explicitly exclude that it acts as a proxy of the actual causal
variant(s) within hGH/CSH cluster modulating the growth poten-
tial. Here, we speculate that alternative alleles of this SNP
(c.171 þ 50C > A) located in intron 2 may modulate splicing pat-
terns and expression of GH2, encoding in total four splice variants
[9]. Interestingly, one of the GH2 gene alternative mRNA tran-
scripts, GH2-4 (20-kDa hGH-V) skips the regular acceptor site in
intron 2 and uses alternative site 45 bp downstream within exon 3
[30]. Functional studies on human pituitary growth hormone (GH)
encoding GH1 (homologous to GH2) have indicated that a speciﬁc
secondary structure within the native human GH transcript con-
trols the relative utilization of the two competing splice-acceptor
sites with the consequent generation of two functionally distinct
hormone isoforms [31]. The deleted region (identical in GH1 and
GH2) involves receptor binding site 1 and secreted hormone has
therefore lower activity for GH receptor and GH binding protein
[32]. The proﬁle of PGH isoforms during fetal period may not only
contribute to the determination of intra-uterine growth and
metabolism, but may also program the activity of the GH/IGF-1
axis for the post-natal period [33].
Increasing attention is drawn to the in utero programming of
postnatal metabolism and risks for adult disease [34]. Although the
majority of observations have been ascribed to maternal malnu-
trition, infection, exposure to environmental factors or placental
pathology, there is growing evidence that developmental pro-
gramming may be also modulated by genetic factors. A poly-
morphism in the IGF2BP2 gene was shown to interact with fetal
malnutrition to program postnatal glucose metabolism [35]. The
carrier status of the T-allele of rs12979860 upstream of IL28B has
been suggested to contribute to subsequent innate immune
development in children who develop allergic disease, as it corre-
lates with differences in the pro-inﬂammatory proﬁle during the
ﬁrst ﬁve years of life [36]. A recent study showed that many genes
with high expression in mid-gestation placenta have also been
implicated in adult complex disease, promoting the discussion on
the role of placenta in developmental programming [37].In summary, the study reports the association between PGH
encoding GH2 polymorphism and adult height, and promotes dis-
cussions and further research on the role of placental genes in
prenatal programming of humanmetabolism and growth potential.Disclosure statement
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